<DOC>
	<DOCNO>NCT01231412</DOCNO>
	<brief_summary>This randomized phase III trial study well graft-vs-host disease ( GVHD ) prophylaxis work treat patient hematologic malignancy undergo unrelated donor peripheral blood stem cell transplant . Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant ( PBSCT ) help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving total-body irradiation ( TBI ) together fludarabine phosphate ( FLU ) , cyclosporine ( CSP ) , mycophenolate mofetil ( MMF ) , sirolimus transplant may stop happening .</brief_summary>
	<brief_title>Graft-Versus-Host Disease Prophylaxis Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare effectiveness 2 GVHD prophylaxis regimens prevent acute grade II-IV GVHD . SECONDARY OBJECTIVES : I . Compare non-relapse mortality 2 arm . II . Compare survival progression-free survival 2 arm . OUTLINE : Patients randomize 1 2 treatment arm . All patient receive FLU intravenously ( IV ) 30 minute day -4 -2 follow 2-3 Gy TBI day 0 . ARM I : Patients receive CSP orally ( PO ) twice daily ( BID ) day -3 96 taper day 150 MMF PO three time daily ( TID ) day 0-29 BID day 30-150 taper day 180 . ARM II : Patients receive CSP Arm I sirolimus PO daily ( QD ) day -3 150 taper day 180 . Patients also receive MMF PO TID day 0-29 BID day 30-40 . MMF discontinue without taper unless GVHD disease relapse/progression occur . TRANSPLANTATION : Patients undergo allogeneic PBSCT day 0 follow TBI . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Ages &gt; 50 year hematologic malignancy treatable unrelated hematopoietic cell transplant ( HCT ) Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT preexist medical condition prior therapy consider high risk regimen relate toxicity associate high dose transplant ( &gt; 40 % risk transplant relate mortality [ TRM ] ) ; criterion include patient HCTcomorbidity index ( CI ) score &gt; = 1 ; transplant approve inclusion criterion principal investigator collaborate center Fred Hutchinson Cancer Research Center ( FHCRC ) ; child &lt; 12 year must discuss FHCRC principal investigator ( PI ) prior registration Ages = &lt; 50 year age chronic lymphocytic leukemia ( CLL ) Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT refuse highdose HCT ; transplant must approve inclusion criterion principal investigator collaborate center FHCRC The following disease permit although diagnosis consider approve Patient Care Conference ( PCC ) participate institution ' patient review committee principal investigator Aggressive nonHodgkin lymphoma ( NHL ) histologies diffuse large B cell NHL : eligible autologous HCT , eligible highdose allogeneic HCT , fail autologous HCT Mantle cell NHL : may treat first complete remission ( CR ) ; ( diagnostic lumbar puncture [ LP ] require pretransplant ) Low grade NHL : &lt; 6 month duration CR course conventional therapy CLL : must either : Failed meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain FLU ( another nucleoside analog , e.g . 2Chlorodeoxyadenosine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain FLU ( another nucleoside analog ) ; Failed FLUcyclophosphamide ( CY ) Rituximab ( FCR ) combination chemotherapy time point ; Have `` 17p deletion '' cytogenetic abnormality ; patient receive induction chemotherapy could transplant 1st CR ; Patients diagnosis CLL ( small lymphocytic lymphoma ) diagnosis CLL progress prolymphocytic leukemia ( PLL ) , Tcell CLL PLL Hodgkin lymphoma : must receive failed frontline therapy Multiple myeloma : must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HCT permit Acute myeloid leukemia ( AML ) : must &lt; 5 % marrow blast time transplant Acute lymphocytic leukemia ( ALL ) : must &lt; 5 % marrow blast time transplant Chronic myeloid leukemia ( CML ) : patient 1st chronic phase ( CP1 ) must fail intolerant tyrosinekinase inhibitor ( TKI ) ; patient beyond CP1 accept &lt; 5 % marrow blast time transplant Myelodysplasia ( MDS ) /myeloproliferative syndrome ( MPS ) : patient must &lt; 5 % marrow blast time transplant Waldenstrom 's macroglobulinemia : must fail 2 course therapy DONOR : FHCRC match allow grade 1.0 2.1 : Unrelated donor prospectively : Matched human leukocyte antigen ( HLA ) A , B , C , DRB1 DQB1 high resolution type Only single allele disparity allow HLAA , B , C define high resolution type DONOR : Donors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result ; positive antidonor cytotoxic crossmatch absolute donor exclusion DONOR : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow DONOR : Only filgrastim ( GCSF ) mobilize PBSC permit hematopoietic stem cell ( HSC ) source protocol Patients rapidly progressive intermediate high grade NHL Patients diagnosis chronic myelomonocytic leukemia ( CMML ) Patients refractory anemia excess blast ( RAEB ) receive myelosuppressive chemotherapy i.e . induction chemotherapy Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient AML , ALL CML Presence &gt; = 5 % circulate leukemic blast ( peripheral blood ) detect standard pathology patient MDS/MPS Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant breastfeeding Patients active nonhematological malignancy ( except nonmelanoma skin cancer ) nonhematological malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within 5 year ; exclusion apply patient nonhematologic malignancy require therapy Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Cardiac ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % , total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume one second ( FEV1 ) &lt; 40 % and/or receive supplementary continuous oxygen The FHCRC PI study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Karnofsky score &lt; 60 Lansky Score &lt; 50 Patient poorly control hypertension multiple antihypertensives Human immunodeficiency virus ( HIV ) positive patient Active bacterial fungal infection unresponsive medical therapy All patient receive antifungal therapy voriconazole , posaconazole , fluconazole randomize ARM 2 must sirolimus reduce accord Standard Practice Antifungal Therapy Guidelines The addition cytotoxic agent `` cytoreduction '' exception tyrosine kinase inhibitor ( imatinib ) , cytokine therapy , hydroxyurea , low dose cytarabine , chlorambucil , Rituxan allow within three week initiation condition DONOR : Donor ( center ) exclusively donate marrow DONOR : Donors HIVpositive and/or , medical condition would result increase risk GCSF mobilization harvest PBSC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>